Peter Grauman
Guardant (United States)(US)Myriad Genetics(US)
Publications by Year
Research Areas
Genomics and Rare Diseases, Cancer Genomics and Diagnostics, Acute Myeloid Leukemia Research, Cystic Fibrosis Research Advances, Epigenetics and DNA Methylation
Most-Cited Works
- → Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes(2014)4,619 cited
- → Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells(2013)1,799 cited
- → Acute myeloid leukemia ontogeny is defined by distinct somatic mutations(2014)967 cited
- → Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation(2017)757 cited
- → Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia(2014)194 cited
- → SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia(2017)147 cited
- → Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification(2018)75 cited
- → Sequencing as a first-line methodology for cystic fibrosis carrier screening(2019)34 cited
- → Inhibition of the CRBN-DDB1-CUL4-ROC1 E3 Ubiquitin Ligase Mediates the Anti-Proliferative and Immunomodulatory Properties of Lenalidomide(2012)31 cited
- → Detecting clinically actionable variants in the 3′ exons of PMS2 via a reflex workflow based on equivalent hybrid capture of the gene and its pseudogene(2018)26 cited